{"id":"NCT01789775","sponsor":"Galderma R&D","briefTitle":"Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2013-02-12","resultsPosted":"2014-10-20","lastUpdate":"2014-10-20"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"Drug: CD07805/47 gel","otherNames":[]},{"type":"DRUG","name":"CD07805/47 gel Placebo","otherNames":[]}],"arms":[{"label":"CD07805/47 gel Placebo","type":"PLACEBO_COMPARATOR"},{"label":"CD07805/47 gel","type":"EXPERIMENTAL"}],"summary":"Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea","primaryOutcome":{"measure":"Composite Success Assessment (CEA) and Patient Self Assessment(PSA).","timeFrame":"Day 29","effectByArm":[{"arm":"CD07805/47 Gel Placebo","deltaMin":32,"sd":null},{"arm":"CD07805/47 Gel","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["France","Russia","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["Rosacea","Erythema"]}}